Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study

Detalles Bibliográficos
Autores principales: Ruperto, N, Brunner, H, Horneff, G, Quartier, P, Constantin, T, Berkun, Y, Erguven, M, Kallinich, T, Brik, R, Wulffraat, NM, Ferrandiz, MA, Rutkowska-Sak, L, Ozdogan, H, McCann, L, Lheritier, K, Preiss, R, Tseng, L, Martini, A, Lovell, DJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Oral Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194416/
http://dx.doi.org/10.1186/1546-0096-9-S1-O21

Ejemplares similares

Ejemplares similares